Moderna Makes Case For Sustainable Vaccine Manufacturing In Africa
Announces Plans For $500m Facility
Less than 4% of the population in Africa has been immunized against COVID-19 and in some quarters the finger of blame has been pointed at the pharma industry. Believing the situation requires a long-term strategy, Moderna is going to build a plant on the continent with the goal of producing up to 500 million doses of vaccines each year.
You may also be interested in...
More COVID-19 vaccines are beginning to flow into Africa, as coordination between partner organizations and African governmental agencies improves. However, gaps remain in cold chain storage, information flow on the ground is lagging and vaccine hesitancy persists. Also, pandemic-related economic depression in some African countries is jeopardizing procurement and access to vaccines.
Discussion of the launch trajectory for the twice-yearly cholesterol therapy dominated the marketing portion of Novartis’s investor event and the firm is confident the foundations have been laid to push strong sales growth by the second half of next year.
PARP inhibitors have had great success in treating a number of cancers but the German major has placed a $65m bet that Nerviano's selective PARP1 approach could produce a safer and more efficacious option.